BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1231726)

  • 1. Effect of tri- and tetra-O-(beta-hydroxyethyl)-rutoside on red blood cell aggregation of human blood.
    van Haeringen NJ
    Bibl Anat; 1975; 13():197-9. PubMed ID: 1231726
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of o-(beta-hydroxyethyl)-rutosides on the microrheology of human blood under defined flow conditions.
    Schmid-Schönbein H; Volger E; Weiss J; Brandhuber M
    Vasa; 1975; 4(3):263-70. PubMed ID: 1179829
    [No Abstract]   [Full Text] [Related]  

  • 3. [Efficacy of troxerutin on the flow properties of blood under defined conditions of circulation. A double-blind study of patients with diabetic retinopathy and arteriosclerotic retinopathy].
    Gallasch G; Dörfer C; Schmitt T; Stage A
    Klin Monbl Augenheilkd; 1985 Jul; 187(1):30-5. PubMed ID: 3906246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of some semisynthetic rutoside derivatives on human platelets.
    Kahlé LH; Dannijs GJ; Ten Cate JW
    Bibl Anat; 1975; 13():263-4. PubMed ID: 1231745
    [No Abstract]   [Full Text] [Related]  

  • 5. o-(beta-Hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment.
    Bull JM; Strebel FR; Sunderland BA; Bulger RE; Edwards M; Siddik ZH; Newman RA
    Cancer Res; 1988 Apr; 48(8):2239-44. PubMed ID: 3349489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of O-(beta-hydroxyethyl)-rutoside (venoruton) on the adherence of leukocytes in patients with arteriosclerosis obliterans of the lower limbs].
    Lukjan H; Szpak A; Bodzenta A; Bielawiec M; Rosc D; Chyzy R
    Pol Arch Med Wewn; 1985 Jun; 73(6):345-50. PubMed ID: 3880372
    [No Abstract]   [Full Text] [Related]  

  • 7. Stimulation and inhibition of biosynthesis of prostaglandins in human skin by some hydroxyethylated rutosides.
    Arturson G; Jonsson CE
    Prostaglandins; 1975 Dec; 10(6):941-8. PubMed ID: 1208886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of hydroxyethylrutosides (HR): metabolism of [14C]-HR in man.
    Hackett AM; Griffiths LA; Luyckx AS; van Cauwenberge H
    Arzneimittelforschung; 1976; 26(5):925-8. PubMed ID: 989368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of O-(beta-hydroxyethyl)-rutoside or venoruton on lactate dehydrogenase of human cultured varicose veins.
    Matagne D; Hamoir G
    Biochem Pharmacol; 1975 Aug; 24(16):1491-4. PubMed ID: 1191306
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of o-(beta-hydroxyethyl)-rutoside in lymphangiography.
    Broks PD
    AJR Am J Roentgenol; 1977 Feb; 128(2):263-5. PubMed ID: 401613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analgesic effect of O-(beta-hydroxy ethyl)rutoside in mice.
    Ramaswamy S; Pillai NP; Gopalakrishnan V; Parmar NS; Ghosh MN
    Indian J Exp Biol; 1985 Apr; 23(4):219-20. PubMed ID: 4077117
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of HR (O-Beta-Hydroxyethylo-Rutoside, Venoruton) on the deformability of erythrocytes in patients with arteriosclerosis obliterans of lower limbs.
    Lukjan H; Rość D; Chyzy R; Bodzenta A; Szpak A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(1):191-6. PubMed ID: 2581865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Venoruton--used not only in venopathies? Symposium on O-(beta-hydroxyethyl)-rutoside (=Venoruton) in vascular diseases].
    ZFA (Stuttgart); 1981 Sep; 57(26):1758-60. PubMed ID: 7303836
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of large doses of a flavonoid O-(betahydroxyethyl)-rutoside on some aspects of venous circulation].
    Forconi S; Guerrini M
    Clin Ter; 1977 Feb; 80(3):229-55. PubMed ID: 852233
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of O-(beta-hydroxyethyl)-rutoside on wound healing in the rat.
    Wilhelmi G
    Pharmacology; 1979; 19(2):82-5. PubMed ID: 531085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HPLC determination of troxerutin in plasma and urine following oral administration in man].
    Dittrich P; Ostrowski J; Beubler E; Schraven E; Kukovetz W
    Arzneimittelforschung; 1985; 35(4):765-7. PubMed ID: 4015744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disposition and metabolism of 3',4',7-tri-O-(beta-hydroxyethyl)rutoside and 7-mono-O-(beta-hydroxyethyl)rutoside in the mouse.
    Hackett AM; Griffiths LA
    Xenobiotica; 1977 Oct; 7(10):641-51. PubMed ID: 910465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of O-(beta-hydroxyethyl)-rutosides (HR) on the skin capillary resistance of rats.
    Gábor M
    Arzneimittelforschung; 1981; 31(3):442-5. PubMed ID: 7194669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O-(beta-hydroxyethyl)-rutoside (Venoruton) fails to block histamine or bradykinin-induced edema formation in the canine forelimb perfused at constant arterial inflow.
    Dobbins DE; Soika CY; Dabney JM
    Microcirc Endothelium Lymphatics; 1984 Oct; 1(5):509-23. PubMed ID: 6546155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the effects of betabeta'-iminodipropionitrile and O-(beta-hydroxyethyl)-rutoside on ADP-activated aggregation of rat platelets in relation to the development of diabetic microangiopathy.
    Pollock J; Heath H
    Biochem Pharmacol; 1975 Feb; 24(3):397-400. PubMed ID: 1125047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.